Home

Jeffrey W. Albers

CIK 1638474 · CEO AND PRESIDENT · last filed 2026-06-25

Jeffrey W. Albers is a CEO AND PRESIDENT who has filed 112 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for KYMR, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$64.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.73M

Companies

5

Total Filings

112

Lifetime Open-Market Net

-$64.49M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KYMR Director 0 $106.16 $0 -$1.80M 13 2026-06-25
SYRE Director 27,360 $99.96 $2.73M -$257.2K 6 2026-05-29
Blueprint Medicines Corp (BPMC) Delisted Director 0 $129.46 $0 -$62.43M 69 2025-07-21
Spyre Therapeutics, Inc. (AGLE) Delisted Director — $12.01 — $0 1 2023-11-27
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Director 260 $11.19 $2.9K $0 5 2022-06-30

Recent Filings

112 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 KYMR Grant (A) — $0 EDGAR
2026-05-29 SYRE Grant (A) — $0 EDGAR
2025-12-08 KYMR Notice (144) −5,000 -$333.1K EDGAR
2025-12-08 KYMR Mixed — -$377.9K EDGAR
2025-10-14 KYMR Notice (144) −5,000 -$286.1K EDGAR
2025-10-14 KYMR Mixed — -$244.2K EDGAR
2025-07-21 Blueprint Medicines Corp (BPMC) Delisted Mixed −150,532 $0 EDGAR
2025-06-26 KYMR Grant (A) — $0 EDGAR
2025-06-24 Blueprint Medicines Corp (BPMC) Delisted Grant (A) +3,902 $499.9K EDGAR
2025-06-03 KYMR Notice (144) −6,349 -$273.8K EDGAR
Showing 1–10 of 112
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.